2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 321

Effects of Bariatric Surgery on Long-Term Quality of Life Outcomes for Obese Patients with Osteoarthritis
Abstract Number: 2237

Effects of Coffee Consumption on Serum Uric Acid. a Systematic Review and Meta-Analysis
Abstract Number: 1491

Effects of Drug Induced Toxicity on Patient Reported Outcomes in Early Rheumatoid Arthritis Treated-to-Target Using Conventional Triple DMARD Therapy
Abstract Number: 216

Effects of Monosodium Urate Crystals on Mlo-Y4 Cell Viability; Is There a Role for Osteocytes in Erosive Gout?
Abstract Number: 2355

Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Serum Uric Acid Levels: A Randomized Controlled Trial
Abstract Number: 2489

Effects of Two Interventions on Rheumatologists Adherence to Optimal Care Recommendations in Rheumatoid Arthritis: A Combined before/after and Randomized Controlled Trial
Abstract Number: 2352

Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study
Abstract Number: 3219

Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study
Abstract Number: 2428

Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis
Abstract Number: 2363

Efficacy and Safety of Adrenocorticotropic Hormone Gel (Acthar Gel ®) in Refractory Dermatomyositis or Polymyositis
Abstract Number: 2422

Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study
Abstract Number: 248

Efficacy and Safety of Canakinumab in Patients with CAPS Aged <24 Months: Results from an Open-Label, Multicenter, Phase III Trial
Abstract Number: 2144

Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis
Abstract Number: 4L

Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Abstract Number: 2350

Efficacy and Safety of Febuxostat in 55 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Results from a Retrospective Multicenter Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].